Vontobel Holding Ltd. lifted its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 13.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,594 shares of the company’s stock after buying an additional 2,677 shares during the quarter. Vontobel Holding Ltd.’s holdings in Kenvue were worth $523,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Cornerstone Wealth Group LLC lifted its stake in Kenvue by 176.2% in the 1st quarter. Cornerstone Wealth Group LLC now owns 350,371 shares of the company’s stock worth $7,519,000 after purchasing an additional 223,537 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Kenvue by 56.2% in the first quarter. Janney Montgomery Scott LLC now owns 1,840,875 shares of the company’s stock worth $39,505,000 after purchasing an additional 662,666 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Kenvue in the first quarter worth $1,050,000. Norden Group LLC bought a new stake in Kenvue during the first quarter valued at $1,792,000. Finally, Lorne Steinberg Wealth Management Inc. grew its position in Kenvue by 59.0% during the second quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company’s stock worth $2,812,000 after buying an additional 57,375 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Kenvue Price Performance
Shares of NYSE:KVUE opened at $22.93 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The stock has a market cap of $43.91 billion, a PE ratio of 29.40, a PEG ratio of 2.76 and a beta of 1.40. The company’s fifty day moving average is $22.30 and its 200 day moving average is $20.22. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.55.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.
Analyst Ratings Changes
Several analysts have weighed in on KVUE shares. JPMorgan Chase & Co. raised their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. UBS Group raised their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Piper Sandler lifted their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $22.20.
Check Out Our Latest Analysis on Kenvue
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
- Five stocks we like better than Kenvue
- What is Short Interest? How to Use It
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- 3 Tickers Leading a Meme Stock Revival
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.